One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Nuvation Bio  logo
Nuvation Bio NUVB
$ 3.79 -1.04%
report update icon

Quarterly report 2026-Q3
added 11-04-2026

Nuvation Bio Financial Statements 2025-2011 | NUVB

Annual Financial Statements Nuvation Bio

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

1.99 B 505 M 414 M 360 M 1.21 B - - - - - - - - - -

Shares

342 M 269 M 219 M 217 M 198 M - - - - - - - - - -

Historical Prices

5.83 1.88 1.89 1.66 6.1 10.2 - - - - - - - - -

Net Income

-205 M -568 M -75.8 M -104 M -86.8 M - - - - - - - - - -

Revenue

62.9 M 7.87 M - - - - - - - - - - - - -

Cost of Revenue

- 7.08 M - - - - - - - - - - - - -

Gross Profit

- 795 K - - - - - - - - - - - - -

Operating Income

-213 M -593 M -99.8 M -120 M -93.3 M -43.6 M - - - - - - - - -

Interest Expense

10.1 M -109 K - - - - - - - - - - - - -

EBITDA

-211 M -592 M -99.6 M -120 M -93.1 M - - - - - - - - - -

Operating Expenses

276 M 600 M 99.8 M 120 M 93.3 M - - - - - - - - - -

General and Administrative Expenses

152 M 69.2 M 28.5 M 31.9 M 24.3 M - - - - - - - - - -

All numbers in USD currency

Quarterly Income Statement Nuvation Bio

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

352 M 349 M 347 M 944 342 M 341 M 339 M 22.9 K 274 M 245 M 219 M 38 219 M 219 M 219 M 598 218 M 217 M 213 M 198 M 207 M 204 M 170 M 149 M 91.8 K 88.7 M 85.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-41.9 M -62.8 M 5.4 M -36.6 M -55.8 M -59 M -53.2 M -49.4 M -41.2 M -462 M -14.8 M -13.8 M -19.6 M -20.6 M -21.7 M -20.8 M -27.2 M -34.9 M -21.3 M -25.1 M -22 M -19.3 M -20.4 M - -11 M -8.6 M -8.75 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

45 M 31.7 M 83.2 M 41.9 M 13.1 M 4.83 M 3.08 M 5.71 M 727 K 1.44 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - - - 3.35 M 2.58 M 2.09 M 4.22 M 1.52 M 1.35 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - 9.77 M 2.26 M 990 K 1.5 M -788 K 88 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-42.2 M -51 M 3.88 M -34 M -56.4 M -63.6 M -59 M -53.9 M -48.1 M -470 M -20.2 M -20.8 M -26.3 M -26.1 M -26.5 M -24.3 M -29.3 M -37.9 M -28.2 M -29.6 M -22.8 M -20.4 M -20.5 M - -11.5 M -9.02 M -9.22 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

881 K - - - 5.12 M 266 K - - - 132 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-42.2 M -50.5 M 4.42 M -33.5 M -55.9 M -63.2 M -58.7 M -53.7 M -47.9 M -470 M -20.1 M -20.8 M -26.3 M -26.1 M -26.5 M -24.3 M -29.3 M -37.8 M -28.1 M -29.6 M -22.7 M -20.4 M -20.5 M - -11.5 M -8.97 M -9.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

87.2 M 82.7 M 79.3 M 75.9 M 69.6 M 68.4 M 62.1 M 62.5 M 47.3 M 470 M 20.2 M 20.8 M 26.3 M 26.1 M 26.5 M 24.3 M 29.3 M 37.9 M 28.2 M 29.6 M 22.8 M 20.4 M 20.5 M - 11.5 M 9.02 M 9.22 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

42.6 M 42.6 M 38.3 M 40.3 M 37.4 M 38.5 M 35.4 M 26.1 M 19.6 M 16.2 M 7.36 M 5.48 M 7.78 M 7.54 M 7.73 M 7.46 M 8.04 M 8.95 M 7.46 M 7.61 M 5.67 M 6.4 M 4.6 M - 2.92 M 1.67 M 1.92 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Nuvation Bio NUVB
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Nuvation Bio plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Mesoblast Limited Mesoblast Limited
MESO
$ 10.9 -2.5 % $ 13.2 B australiaAustralia
Mirum Pharmaceuticals Mirum Pharmaceuticals
MIRM
$ 96.15 0.67 % $ 4.83 B usaUSA
MannKind Corporation MannKind Corporation
MNKD
$ 3.85 -2.66 % $ 1.18 B usaUSA
Dyadic International Dyadic International
DYAI
$ 0.29 -6.53 % $ 10.5 M usaUSA
Merck & Co. Merck & Co.
MRK
$ 133.34 0.4 % $ 334 B usaUSA
Moderna Moderna
MRNA
$ 195.25 -2.05 % $ 76 B usaUSA
NuCana plc NuCana plc
NCNA
$ 0.75 4.39 % $ 8.42 B britainBritain
Novartis AG Novartis AG
NVS
$ 150.51 -0.47 % $ 292 B schweizSchweiz
Puma Biotechnology Puma Biotechnology
PBYI
$ 7.05 -1.05 % $ 353 M usaUSA
Fulcrum Therapeutics Fulcrum Therapeutics
FULC
$ 3.69 -0.67 % $ 281 M usaUSA
PDS Biotechnology Corporation PDS Biotechnology Corporation
PDSB
$ 0.79 -2.58 % $ 36.6 M usaUSA
Geron Corporation Geron Corporation
GERN
$ 0.87 -4.76 % $ 580 M usaUSA
Pharming Group N.V. Pharming Group N.V.
PHAR
$ 11.54 -5.18 % $ 7.95 B niderlandNiderland
Phathom Pharmaceuticals Phathom Pharmaceuticals
PHAT
$ 4.65 -8.46 % $ 339 M usaUSA
Genmab A/S Genmab A/S
GMAB
$ 50.36 -1.93 % $ 3.26 B danmarkDanmark
Gossamer Bio Gossamer Bio
GOSS
$ 10.69 -4.81 % $ 2.44 B usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.14 -0.73 % $ 5.53 B spainSpain
Liquidia Corporation Liquidia Corporation
LQDA
$ 54.39 -3.96 % $ 4.68 B usaUSA
GlaxoSmithKline plc GlaxoSmithKline plc
GSK
$ 47.8 -0.05 % $ 194 B britainBritain
MediciNova MediciNova
MNOV
$ 1.3 2.36 % $ 63.8 M usaUSA
PTC Therapeutics PTC Therapeutics
PTCT
$ 56.23 -3.59 % $ 4.47 B usaUSA
Pulmatrix Pulmatrix
PULM
$ 1.24 -12.34 % $ 4.53 B usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
$ 1.05 -3.67 % $ 70.7 M germanyGermany
Immunome Immunome
IMNM
$ 15.69 -5.54 % $ 1.37 B usaUSA
Immuron Limited Immuron Limited
IMRN
$ 0.9 5.87 % $ 208 M australiaAustralia
Incyte Corporation Incyte Corporation
INCY
$ 114.5 -1.19 % $ 22.4 B usaUSA
INmune Bio INmune Bio
INMB
$ 0.82 -8.41 % $ 20.3 M usaUSA
Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Limited
RDY
$ 14.88 0.24 % $ 12.4 B indiaIndia
Regeneron Pharmaceuticals Regeneron Pharmaceuticals
REGN
$ 920.38 -0.22 % $ 96.3 B usaUSA
Ionis Pharmaceuticals Ionis Pharmaceuticals
IONS
$ 26.58 -2.37 % $ 4.25 B usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 1.06 -10.92 % $ 48.4 M israelIsrael
Ironwood Pharmaceuticals Ironwood Pharmaceuticals
IRWD
$ 4.68 -0.53 % $ 757 M usaUSA
Kala Pharmaceuticals Kala Pharmaceuticals
KALA
$ 2.73 -9.61 % $ 22.2 M usaUSA
Intellia Therapeutics Intellia Therapeutics
NTLA
$ 10.02 5.24 % $ 1.09 B usaUSA
Adagene Adagene
ADAG
$ 1.8 -10.56 % $ 106 M chinaChina
Denali Therapeutics Denali Therapeutics
DNLI
$ 18.43 1.29 % $ 3.18 B usaUSA
Pfizer Pfizer
PFE
$ 27.4 -0.62 % $ 156 B usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 10.56 -6.26 % $ 4.38 B irlandaIrlanda
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 11.08 -0.81 % $ 100 M usaUSA
Editas Medicine Editas Medicine
EDIT
$ 1.63 -4.68 % $ 145 M usaUSA
Kiniksa Pharmaceuticals, Ltd. Kiniksa Pharmaceuticals, Ltd.
KNSA
$ 93.83 0.32 % $ 6.96 B usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 27.54 -4.24 % $ 1.6 B usaUSA
Royalty Pharma plc Royalty Pharma plc
RPRX
$ 68.45 1.08 % $ 29.4 B usaUSA
Equillium Equillium
EQ
$ 1.06 -5.36 % $ 60.7 M usaUSA
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 1.32 -5.04 % $ 75.1 M usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 2.42 -1.17 % $ 128 M usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 17.1 -2.79 % $ 2.88 B usaUSA
Atossa Therapeutics Atossa Therapeutics
ATOS
$ 1.6 -8.86 % $ 13.8 M usaUSA
Cleveland BioLabs, Inc. Cleveland BioLabs, Inc.
CBLI
- -7.31 % $ 49 M usaUSA
Rhythm Pharmaceuticals Rhythm Pharmaceuticals
RYTM
$ 112.31 -3.84 % $ 7.3 B usaUSA